Buy RARE by Nov 14, 2026.

Ok, the ticket is RARE, Ultragenyx Pharmaceutical Inc., with a market cap of $2.6B on revenues of $717M TTM. They already have four approved drugs bringing in revenue. They are however currently unprofitable which is the issue and why they are undervalued because the market is pricing in a capital raise. Now here’s the value proposition, in my humble opinion, what the market IS NOT PRICING IN, and thus where the opportunity lays. Two PFUDA dates approaching within the next …